Hepatocellular carcinoma

HCC · Oncology · 4 drugs · 2 indications

Primary liver cancer. Often associated with hepatitis or cirrhosis.

Competitive Landscape (4 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
volrustomig	AZN	PD-1 + TIGIT dual blockade	Bispecific	IV	PHASE3
Imjudo	AZN	CTLA-4 inhibitor	Antibody	IV	APPROVED
Tecentriq	ROG.SW	PD-L1 inhibitor	Antibody	IV	APPROVED
Keytruda	MRK	PD-1 inhibitor	Antibody	IV	APPROVED

Indications (2)

Hepatocellular Carcinoma

HCC

Tecentriq APPROVEDKeytruda APPROVED

Upcoming Catalysts

Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)CLINICAL

MRK2026

Keytruda - LOE PreparationCOMPETITIVE

MRKOngoing

Data from Supabase · Updated 2026-03-24